191 related articles for article (PubMed ID: 16871471)
1. Bupropion augmentation in the treatment of chronic fatigue syndrome with coexistent major depression episode.
Schönfeldt-Lecuona C; Connemann BJ; Wolf RC; Braun M; Freudenmann RW
Pharmacopsychiatry; 2006 Jul; 39(4):152-4. PubMed ID: 16871471
[TBL] [Abstract][Full Text] [Related]
2. Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion.
Pae CU; Lim HK; Han C; Patkar AA; Steffens DC; Masand PS; Lee C
Expert Rev Neurother; 2007 Oct; 7(10):1251-63. PubMed ID: 17939764
[TBL] [Abstract][Full Text] [Related]
3. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder.
Herrera-Guzmán I; Gudayol-Ferré E; Lira-Mandujano J; Herrera-Abarca J; Herrera-Guzmán D; Montoya-Pérez K; Guardia-Olmos J
Psychiatry Res; 2008 Jul; 160(1):72-82. PubMed ID: 18501971
[TBL] [Abstract][Full Text] [Related]
4. Open-label study of s-citalopram therapy of chronic fatigue syndrome and co-morbid major depressive disorder.
Amsterdam JD; Shults J; Rutherford N
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):100-6. PubMed ID: 17804135
[TBL] [Abstract][Full Text] [Related]
5. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S
Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754
[TBL] [Abstract][Full Text] [Related]
7. An IgM-mediated immune response directed against nitro-bovine serum albumin (nitro-BSA) in chronic fatigue syndrome (CFS) and major depression: evidence that nitrosative stress is another factor underpinning the comorbidity between major depression and CFS.
Maes M; Mihaylova I; Kubera M; Leunis JC
Neuro Endocrinol Lett; 2008 Jun; 29(3):313-9. PubMed ID: 18580855
[TBL] [Abstract][Full Text] [Related]
8. MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression.
Mihaljevic Peles A; Bozina N; Sagud M; Rojnic Kuzman M; Lovric M
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1439-44. PubMed ID: 18550244
[TBL] [Abstract][Full Text] [Related]
9. Should adjunctive antipsychotic treatment be continued in remitted patients with depression?
Uchida H; Suzuki T; Watanabe K; Kashima H
Psychiatry Clin Neurosci; 2009 Feb; 63(1):126. PubMed ID: 19154222
[No Abstract] [Full Text] [Related]
10. Cognitive deficits in patients with chronic fatigue syndrome compared to those with major depressive disorder and healthy controls.
Constant EL; Adam S; Gillain B; Lambert M; Masquelier E; Seron X
Clin Neurol Neurosurg; 2011 May; 113(4):295-302. PubMed ID: 21255911
[TBL] [Abstract][Full Text] [Related]
11. An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners.
Moss EL; Simpson JS; Pelletier G; Forsyth P
Psychooncology; 2006 Mar; 15(3):259-67. PubMed ID: 16041840
[TBL] [Abstract][Full Text] [Related]
12. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability.
Thase ME; Clayton AH; Haight BR; Thompson AH; Modell JG; Johnston JA
J Clin Psychopharmacol; 2006 Oct; 26(5):482-8. PubMed ID: 16974189
[TBL] [Abstract][Full Text] [Related]
13. Depression and psoriasis comorbidity. Treatment with paroxetine: two case reports.
Luis Blay S
Ann Clin Psychiatry; 2006; 18(4):271-2. PubMed ID: 17162628
[No Abstract] [Full Text] [Related]
14. Psychomotor functioning in chronic fatigue syndrome and major depressive disorder: a comparative study.
Schrijvers D; Van Den Eede F; Maas Y; Cosyns P; Hulstijn W; Sabbe BG
J Affect Disord; 2009 May; 115(1-2):46-53. PubMed ID: 18817977
[TBL] [Abstract][Full Text] [Related]
15. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
[TBL] [Abstract][Full Text] [Related]
16. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
[TBL] [Abstract][Full Text] [Related]
17. Clinical application of paroxetine for tapering benzodiazepine use in non-major-depressive outpatients visiting an internal medicine clinic.
Nakao M; Takeuchi T; Nomura K; Teramoto T; Yano E
Psychiatry Clin Neurosci; 2006 Oct; 60(5):605-10. PubMed ID: 16958945
[TBL] [Abstract][Full Text] [Related]
18. Major depressive disorder, antidepressants, and sexual dysfunction.
Clayton AH; Montejo AL
J Clin Psychiatry; 2006; 67 Suppl 6():33-7. PubMed ID: 16848675
[TBL] [Abstract][Full Text] [Related]
19. Acute dystonia resulting from abrupt bupropion discontinuation.
Wang HY; Chou WJ; Huang TY; Hung CF
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):766-8. PubMed ID: 17218049
[TBL] [Abstract][Full Text] [Related]
20. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression.
Maron E; Tammiste A; Kallassalu K; Eller T; Vasar V; Nutt DJ; Metspalu A
Eur Neuropsychopharmacol; 2009 Jun; 19(6):451-6. PubMed ID: 19272758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
